Effect of diarrhea on the humoral response to oral polio vaccination.
OBJECTIVE
The purpose of this study was to measure the effect of concurrent diarrheal illness on seroconversion to trivalent oral polio vaccine (OPV).


METHODS
Six- to 16-week-old infants with acute diarrhea and age-matched controls received single doses of OPV at enrollment, 4 weeks after enrollment and 8 weeks after enrollment. Serum specimens were obtained at enrollment, before the second OPV dose and 4 weeks after the third OPV dose for measurement of antibody titers to polio virus by the microneutralization assay.


RESULTS
Four weeks after the first OPV dose, the serologic responses to poliovirus types 2 and 3 in the case cohort were lower by 26 and 34%, respectively, than in the control cohort (P < 0.002 for both comparisons). Poliovirus type 2 and 3 geometric mean antibody titers in the diarrhea cohort were approximately 50% of the geometric mean antibody titers in the control cohort (235 (95% confidence interval (CI) 154 to 359) vs. 446 (95% CI 350 to 569) and 64 (95% CI 45 to 90) vs. 112 (95% CI 88 to 143), respectively, P < 0.01 for both comparisons). After the third OPV dose the seroconvertion rates to poliovirus types 2 and 3 each remained about 10% lower in the case cohort than in the control cohort, but the differences were not statistically significant.


CONCLUSIONS
Concurrent acute diarrhea adversely affects seroconvertion rates of type 2 and 3 polioviruses among infants in Bangladesh receiving the first dose of trivalent OPV.
Myaux
J A
JA
International Centre for Diarrheal Disease Research, Bangladesh, Dhaka.
Unicomb
L
L
Besser
R E
RE
Modlin
J F
JF
Uzma
A
A
Islam
A M
AM
Santosham
M
M
D000208:Acute Disease; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis*; D000917:Antibody Formation; D015331:Cohort Studies; D003967:Diarrhea / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D011051:Poliomyelitis / Q000517:prevention & control*; D017955:Poliovirus / Q000276:immunology*; D011055:Poliovirus Vaccine, Oral / Q000276:immunology*; D014611:Vaccination
D000914:Antibodies, Viral; D011055:Poliovirus Vaccine, Oral